InflaRx NV
NASDAQ:IFRX
InflaRx NV
Cost of Revenue
InflaRx NV
Cost of Revenue Peer Comparison
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
InflaRx NV
NASDAQ:IFRX
|
Cost of Revenue
-€752.8k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
BioNTech SE
NASDAQ:BNTX
|
Cost of Revenue
-€599.8m
|
CAGR 3-Years
-117%
|
CAGR 5-Years
-112%
|
CAGR 10-Years
N/A
|
|
MorphoSys AG
XETRA:MOR
|
Cost of Revenue
-€32.8m
|
CAGR 3-Years
-44%
|
CAGR 5-Years
-37%
|
CAGR 10-Years
N/A
|
|
CureVac NV
NASDAQ:CVAC
|
Cost of Revenue
-€116.3m
|
CAGR 3-Years
-102%
|
CAGR 5-Years
-46%
|
CAGR 10-Years
N/A
|
|
Immatics NV
NASDAQ:IMTX
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Biotest AG
XETRA:BIO
|
Cost of Revenue
-€528.9m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-6%
|
See Also
What is InflaRx NV's Cost of Revenue?
Cost of Revenue
-752.8k
EUR
Based on the financial report for Mar 31, 2024, InflaRx NV's Cost of Revenue amounts to -752.8k EUR.